Cargando…

Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants

Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthc...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Panke, Xu, Kai, Faraone, Julia N., Goodarzi, Negin, Zheng, Yi-Min, Carlin, Claire, Bednash, Joseph S., Horowitz, Jeffrey C., Mallampalli, Rama K., Saif, Linda J., Oltz, Eugene M., Jones, Daniel, Gumina, Richard J., Liu, Shan-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515800/
https://www.ncbi.nlm.nih.gov/pubmed/37745517
http://dx.doi.org/10.1101/2023.09.11.557206
_version_ 1785109021795024896
author Qu, Panke
Xu, Kai
Faraone, Julia N.
Goodarzi, Negin
Zheng, Yi-Min
Carlin, Claire
Bednash, Joseph S.
Horowitz, Jeffrey C.
Mallampalli, Rama K.
Saif, Linda J.
Oltz, Eugene M.
Jones, Daniel
Gumina, Richard J.
Liu, Shan-Lu
author_facet Qu, Panke
Xu, Kai
Faraone, Julia N.
Goodarzi, Negin
Zheng, Yi-Min
Carlin, Claire
Bednash, Joseph S.
Horowitz, Jeffrey C.
Mallampalli, Rama K.
Saif, Linda J.
Oltz, Eugene M.
Jones, Daniel
Gumina, Richard J.
Liu, Shan-Lu
author_sort Qu, Panke
collection PubMed
description Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines.
format Online
Article
Text
id pubmed-10515800
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-105158002023-09-23 Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants Qu, Panke Xu, Kai Faraone, Julia N. Goodarzi, Negin Zheng, Yi-Min Carlin, Claire Bednash, Joseph S. Horowitz, Jeffrey C. Mallampalli, Rama K. Saif, Linda J. Oltz, Eugene M. Jones, Daniel Gumina, Richard J. Liu, Shan-Lu bioRxiv Article Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines. Cold Spring Harbor Laboratory 2023-09-12 /pmc/articles/PMC10515800/ /pubmed/37745517 http://dx.doi.org/10.1101/2023.09.11.557206 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Qu, Panke
Xu, Kai
Faraone, Julia N.
Goodarzi, Negin
Zheng, Yi-Min
Carlin, Claire
Bednash, Joseph S.
Horowitz, Jeffrey C.
Mallampalli, Rama K.
Saif, Linda J.
Oltz, Eugene M.
Jones, Daniel
Gumina, Richard J.
Liu, Shan-Lu
Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
title Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
title_full Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
title_fullStr Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
title_full_unstemmed Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
title_short Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
title_sort immune evasion, infectivity, and fusogenicity of sars-cov-2 omicron ba.2.86 and flip variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515800/
https://www.ncbi.nlm.nih.gov/pubmed/37745517
http://dx.doi.org/10.1101/2023.09.11.557206
work_keys_str_mv AT qupanke immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT xukai immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT faraonejulian immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT goodarzinegin immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT zhengyimin immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT carlinclaire immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT bednashjosephs immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT horowitzjeffreyc immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT mallampalliramak immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT saiflindaj immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT oltzeugenem immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT jonesdaniel immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT guminarichardj immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants
AT liushanlu immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants